MedTrace Logo

Magnetic Resonance Imaging Study of Geriatric Depression

NCT00245557 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-03-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression. We hypothesized that concentrations of high energy metabolites would be lower in depressed elderly compared to non-depressed.

Conditions

Interventions

DRUG

Sertraline

Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day. Duration of treatment was 12 weeks.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Brent Forester, M.D · Mclean Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245557 on ClinicalTrials.gov